Subscribe

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Opdivo plus Platinum-Based Chemotherapy FDA Approved as First Neoadjuvant Treatment in Early-Stage NSCLC

JHOP - April 2022 Vol 12, No 2 - FDA Oncology Update, Lung Cancer, Checkpoint Inhibitors
NEW INDICATIONS
Download PDF

On March 4, 2022, the FDA accelerated the approval of the PD-1 inhibitor nivolumab (Opdivo; Bristol Myers Squibb) in combination with platinum-doublet chemotherapy for the neoadjuvant treatment of adults with resectable non–small-cell lung cancer (NSCLC). This represents the first FDA approval for neoadjuvant therapy for early-stage NSCLC.

The efficacy was evaluated in the CheckMate-816 study, a randomized, open-label clinical trial of patients with resectable, stage IB (≥4 cm), stage II, or stage IIIA NSCLC. Patients were enrolled regardless of the tumor PD-1 or PD-L1 status. A total of 358 patients were randomized to nivolumab plus platinum-doublet chemotherapy or to platinum-chemotherapy alone, administered every 3 weeks for up to 3 cycles in each arm.

The main efficacy outcomes were event-free survival (EFS) and pathologic complete response (pCR). The median EFS was 31.6 months (95% confidence interval [CI], 30.2-not reached) in the nivolumab plus chemotherapy arm and 20.8 months (95% CI, 14.0-26.7) in the chemotherapy-alone arm. The hazard ratio was 0.63 (97.38% CI, 0.43-0.91; P = .0052). The pCR rate was 24% (95% CI, 18.0-31.0) with nivolumab plus chemotherapy versus 2.2% (95% CI, 0.6-5.6) with chemotherapy alone.

The most common (≥20%) adverse reactions were nausea, constipation, fatigue, decreased appetite, and rash. The addition of nivolumab to chemotherapy did not lead to more frequent delays or cancellations of surgery. The median lengths of hospital days after definitive surgery, and the rates of adverse reactions related to surgery were similar in both groups.

Related Items
Omisirge FDA Approved for Patients with Hematologic Malignancies to Reduce Time to Neutrophil Recovery and Infection
Online First published on May 12, 2023 in FDA Oncology Update
Padcev plus Keytruda Granted Accelerated FDA Approval for Locally Advanced or Metastatic Urothelial Carcinoma
Online First published on April 24, 2023 in FDA Oncology Update
FDA Approved Zynyz for Metastatic or Recurrent Locally Advanced Merkel-Cell Carcinoma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Approved Tafinlar plus Mekinist for Pediatric Patients with BRAF V600E Mutation–Positive Low-Grade Glioma
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Granted Jemperli Regular Approval for dMMR Endometrial Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
FDA Expanded Eligibility for Verzenio plus Endocrine Therapy in Patients with Early Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Trodelvy Now FDA Approved for HR-Positive, HER2-Negative Breast Cancer
JHOP - April 2023 Vol 13, No 2 published on March 31, 2023 in FDA Oncology Update
Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma
JHOP - February 2023 Vol 13, No 1 published on February 27, 2023 in FDA Oncology Update
© Amplity Health. All rights reserved.